Claims for Patent: 10,213,420

Summary for Patent: 10,213,420

Title:	Combination therapy for treatment of HBV infections
Abstract:	Provided herein is a combination therapy comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog. The combination therapy is useful for the treatment of HBV infection. Also provided herein are compositions comprising a compound of Formula I and peginterferon alfa-2a, or another interferon analog.
Inventor(s):	Hartman; George D. (Lansdale, PA)
Assignee:	NOVIRA THERAPEUTICS, INC. (Doylestown, PA)
Application Number:	15/284,807
Patent Claims:	1. A method of treating an HBV infection in a subject in need thereof, comprising administering to the subject a capsid assembly inhibitor and interferon, wherein the capsid assembly inhibitor is a compound of Formula IVc: ##STR00035## or a pharmaceutically acceptable salt thereof; wherein X is halo; G.sup.1 is hydrogen or halo; G.sup.2 is H, C.sub.1-C.sub.4 alkyl, or halo; and G.sup.4 is H, halo, C.sub.1-C.sub.4 alkyl, or OH. 2. The method of claim 1, wherein the interferon is selected from the group consisting of interferon alpha, interferon alpha-2a, recombinant interferon alpha-2a, peginterferon-alpha-2a, interferon alpha-2b, recombinant interferon alpha-2b, interferon alpha-2b XL, peginterferon alpha-2b, glycosylated interferon alpha-2b, interferon alpha-2c, recombinant interferon alpha-2c, interferon beta, interferon beta-1a, peginterferon beta-1a, interferon delta, interferon lambda, peginterferon lambda-1, interferon omega, interferon tau, gamma interferon, interferon alfacon-1, interferon alpha-nl, interferon alpha-n3, albinterferon alpha-2b, BLX-883, DA-3021, and PEG-Infergen. 3. The method of claim 2, wherein the interferon is selected from the group consisting of peginterferon alpha-2a, peginterferon alpha-2b, glycosylated interferon alpha-2b, peginterferon beta-1a, and peginterferon lambda-1. 4. The method of claim 3, wherein the interferon is peginterferon alpha-2a. 5. The method of claim 1, wherein the interferon and compound of Formula IVc are in a single formulation or unit dosage form. 6. The method of claim 5, further comprising a pharmaceutically acceptable carrier. 7. The method of claim 1, wherein the interferon and compound of Formula I are administered separately. 8. The method of claim 1, wherein the subject is human. 9. The method of claim 1, wherein the treatment comprises administering the interferon and compound of Formula IVc at substantially the same time. 10. The method of claim 1, wherein the treatment comprises administering the interferon and compound of Formula IVc at different times. 11. The method of claim 10, wherein the interferon is administered to the subject, followed by administration of a compound of Formula IVc. 12. The method of claim 10, wherein the compound of Formula IVc is administered to the subject, followed by administration of the interferon. 13. The method of 9, wherein the interferon and compound of Formula IVc are in separate formulations or unit dosage forms. 14. The method of claim 1, wherein the interferon and compound of Formula IVc are administered at dosages that would not be effective when one or both of the interferon and compound of Formula IVc are administered alone, but which amounts are effective in combination. 15. A composition comprising interferon and a compound of Formula IVc: ##STR00036## or a pharmaceutically acceptable salt thereof; wherein X is halo; G.sup.1 is hydrogen or halo; G.sup.2 is H, C.sub.1-C.sub.4 alkyl, or halo; and G.sup.4 is H, halo, C.sub.1-C.sub.4 alkyl, or OH. 16. A method of treating an HBV infection in a subject in need thereof comprising administering to the subject an effective amount of the composition of claim 15. 17. The method of claim 1, wherein the compound of Formula IVc is selected from the group consisting of: ##STR00037## ##STR00038## ##STR00039## ##STR00040## ##STR00041## ##STR00042## or a pharmaceutically acceptable salt thereof. 18. The composition of claim 15, wherein the compound of Formula IVc is selected from the group consisting of: ##STR00043## ##STR00044## ##STR00045## ##STR00046## ##STR00047## ##STR00048## or a pharmaceutically acceptable salt thereof.

Details for Patent 10,213,420

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	May 17, 1996		2034-02-05
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	May 28, 2003		2034-02-05
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	February 27, 2012		2034-02-05
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	October 06, 1997		2034-02-05
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	March 07, 2002		2034-02-05
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	December 17, 2004		2034-02-05
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	December 21, 2012		2034-02-05